pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 38 Non-oncology: 26
Oncology: 12
Under Consideration for Negotiation 26 Non-oncology: 13
Oncology: 13
Completed Negotiations 505 With Letter of Intent: 438
Without agreement: 67
Negotiations That Were Not Pursued 89

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Ogivri BGP Pharma ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Ontruzant Organon Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Kanjinti Amgen Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Inrebic Celgene Inc. Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been prev
Trazimera Pfizer Canada ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Herzuma Teva Canada Limited Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kyprolis Amgen Canada Inc. Treatment of multiple myeloma (including relapsed)
Vyxeos Jazz Pharmaceuticals Canada Inc. For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vascepa HLS Therapeutics Inc. Ischemic events in statin-treated patients

Negotiations that pCPA Decided Not to Pursue in the last four weeks